News Related to H.C. Wainwright

Related coverage linked through entity extraction aliases.

Iovance Biotherapeutics Reports Q4 Revenue Beat, FDA Fast Track for Lung Cancer

Feb 26, 2026

Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.

Analysts Raise Price Targets on Praxis Precision Medicines Following Clinical Progress

Feb 24, 2026

Multiple analysts have raised price targets on Praxis Precision Medicines, with Wolfe Research initiating coverage at $500 and Guggenheim increasing its target to $800, citing strong market potential for ulixacaltamide in essential tremor.